Data +Oct 23, 2026
Positive data — Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephr…▸
high impact
ApprovalOct 16, 2026
FDA approval — Roche Gets FDA Approval for Enspryng in Thyroid Eye Disease▸
high impact
DealOct 13, 2026
Deal — Rona Therapeutics Signs Global RNAi Licensing Agreement with Roche Worth Up to $1.16 Billion in Milestones▸
medium impact
FilingOct 10, 2026
Regulatory filing — Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss▸
medium impact
ApprovalOct 09, 2026
FDA approval — Roche’s Genentech Secures FDA Approval for Tecentriq in Stage III Colon Cancer▸
high impact
Data +Sep 23, 2026
Positive data — Roche’s Sefaxersen Meets Primary Endpoint in Phase III Kidney Disease Trial▸
high impact
Data +Sep 22, 2026
Positive data — Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Typ…▸
high impact
Data +Sep 17, 2026
Positive data — Roche’s Genentech Reports Positive Phase III CELESTIMO Results for Lunsumio in Follicular Lymphoma▸
high impact
FilingSep 10, 2026
Regulatory filing — Roche’s Genentech Gets FDA Priority Review for Enspryng in MOGAD▸
medium impact